Literature DB >> 29332317

Routine use of Day 6 and Day 7 platelets with rapid testing: two hospitals assess impact 1 year after implementation.

Sarah K Harm1, Zbigniew M Szczepiorkowski2,3, Nancy M Dunbar2.   

Abstract

BACKGROUND: In March 2016 the US Food and Drug Administration published a draft guidance to enhance the safety of platelets (PLTs) for transfusion. Options for hospital transfusion services include the use of rapid testing to extend apheresis PLT dating for up to 7 days. This report describes the impact of routine use of Day 6 and Day 7 PLTs at two hospital transfusion services 1 year after implementation of rapid testing for outdate extension. STUDY DESIGN AND METHODS: PLT transfusion and inventory data were obtained from two hospital-based transfusion services for 12 months before and 12 months after implementation of rapid testing to extend the outdate of apheresis PLTs to 7 days.
RESULTS: The outdate rate decreased from 5% to 2% (p < 0.0001) at Hospital 1 and 28% to 14% (p < 0.001) at Hospital 2 after implementation of routine use of Day 6 and Day 7 PLTs. The proportion of apheresis PLT units that underwent secondary screening for bacterial contamination before transfusion in the postimplementation period increased from 33% to 54% at Hospital 1 and from 0% to 31% at Hospital 2.
CONCLUSION: A significant decrease in outdate rate was observed after routine use of Day 6 and Day 7 PLTs. Use of rapid testing to extend PLT outdate also resulted in a larger proportion of PLTs that underwent secondary testing for bacterial contamination before transfusion. These observations demonstrate that use of rapid testing to extend apheresis PLT dating up to 7 days enhances the safety of PLTs for transfusion and decreases wastage of a limited resource.
© 2018 AABB.

Entities:  

Mesh:

Year:  2018        PMID: 29332317     DOI: 10.1111/trf.14473

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  2 in total

1.  ABO-incompatible platelets are associated with increased transfusion reaction rates.

Authors:  Natalie Malvik; Judith Leon; Annette J Schlueter; Chaorong Wu; C Michael Knudson
Journal:  Transfusion       Date:  2020-01-08       Impact factor: 3.157

2.  How do you… decide which platelet bacterial risk mitigation strategy to select for your hospital-based transfusion service?

Authors:  Wen Lu; Meghan Delaney; Willy A Flegel; Paul Ness; Nora Ratcliffe; Darrell J Triulzi; Mark H Yazer; Alyssa Ziman; Nancy M Dunbar
Journal:  Transfusion       Date:  2020-02-06       Impact factor: 3.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.